Key insight: A letter in Nature Methods noting flaws in the CRISPR gene editing system spooked investors today, but it shouldn’t have — because we’ve long known about those problems.

A letter in Nature Methods pointing out potentially dangerous flaws in the CRISPR-Cas9 genome editing system gave biotech investors a sinking feeling on Tuesday, and stocks in genome-editing companies had the same experience. By the close of trading Editas Medicine had fallen nearly 12 percent, Crispr Therapeutics was down more than 5 percent, and Intellia Therapeutics had plunged just over 14 percent.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine